207_Combined course Presentations
Keynote-024: Pembrolizumab vs Chemotherapy as first line therapy in stage IV NSCLC
Phase III trial
Pembrolizumab vs Platinum based doublet
305 patients enrolled
All patients had a PD-L1 expression on
at least 50% of the tumor cells
Reck M. et al. NEJM 2016
Made with FlippingBook